Oritavancin strongly binds with OAS1 (binding affinity: −16.6 kcal/mol) and has also been suggested as a potential COVID-19 treatment option that inhibits cathepsin L and cathepsin B in host cells (late endosomal pathway)33. Here, OAS1 is linked to COVID-19.